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Hyperimmunoglobulinemia D and Periodic Fever Syndrome
The Clinical Spectrum in a Series of 50 Patients
J o o st  P .H . D r e n t h , C ees  J . H a a g s m a , J os  W .M . van  d e r  M e e r , and
t h e  I n t e r n a t io n a l  H y p e r -Ig D St u d y  G r o u p *
Introduction
In 1984, Van der Meer and colleagues (53) de­
scribed 6 patients with periodic fever and a con­
stantly elevated polyclonal IgD and labeled the 
syndrome the hyperimmunoglobulinemia D (hyper- 
IgD) and periodic fever syndrome (called here the 
hyper-IgD syndrome). Similar cases of this new 
syndrome have been reported by others; some of 
these cases have been difficult to diagnose (5, 15,
16, 20, 21, 28, 32, 35, 38, 40, 45, 51, 53, 54). The 
hyper-IgD syndrome has to be distinguished from 
other clinical entities with recurrent high spiking 
fever such as systemic-onset juvenile rheumatoid 
arthritis, adult-onset Still disease, familial Medi­
terranean fever, and familial Hibernian fever (31, 
37, 38, 39, 57). The patients present with a long 
history of recurrent attacks of fever, which are 
frequently preceded by chills and accompanied by 
headache, bilateral cervical lymphadenopathy, and 
occasionally by abdominal pain and diarrhea. Lab­
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oratory analysis invariably reveals a markedly ele­
vated serum level of polyclonal IgD (22, 38, 53). As 
yet, little is known about the etiology and patho­
genesis of the syndrome and treatment remains 
supportive. It has been hypothesized that these 
patients exhibit an uncontrolled type III hypersen­
sitivity reaction possibly with involvement of IgD- 
containing complexes (5, 21, 54). The few isolated 
case reports illustrate only some of the clinical 
characterizations of hyper-IgD and periodic fever 
syndrome, and therefore only an incomplete picture 
of its manifestations is available currently. The 
present study was performed to obtain a compre­
hensive description of the clinical features of this 
syndrome and to clarify its position as a distinct 
entity separate from the other periodic fever syn­
dromes. We collected clinical and laboratory data 
for 50 cases, both published and unpublished, of 
patients with the hyperimmunoglobulinemia D and 
periodic fever syndrome.
Patients and Methods
We conducted a search to obtain data on patients known to 
have hyper-IgD and periodic fever syndrome. Patients with the 
hyper-IgD syndrome referred to the University Hospitals of 
Nijmegen, Utrecht, or Leiden in the Netherlands participated 
in the study. We included patients brought to our attention via 
personal correspondence to 1 of us (J.W.M.M.). A computer- 
aided literature search (Medline, National Library of Medicine, 
Bethesda, MD) using the key words “fever,” “periodic,” and 
“hyper-IgD” was performed for the years 1984 to 1993. The 
reference lists of published reports were examined for additional 
cases. Supplementary information was obtained by question­
naires completed by the attending physicians of the cases and, 
whenever possible, by examining the individual patient charts. 
The International Hyper-IgD Study Group was established to 
improve awareness of, facilitate diagnosis of, and investigate 
novel therapies for this syndrome. The group consists of physi­
cians who were treating these patients. Patients were included 
if they had a history of recurrent fever, defined as a rectal body 
temperature higher than 38.5°C, and an elevated level of serum 
IgD (>100 U/mL) measured when possible at 2 occasions at 
least 1 month apart. Recurrent microbial infections as a cause 
of the periodic fever were ruled out. Data were collected using 
questionnaires with special attention to the following items: age
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at onset of the attacks; length and periodicity of the attacks; 
occurrence of chills before an attack; highest recorded body 
temperature; occurrence of headache, arthralgias, abdominal 
pains, diarrhea, and vomiting; ancestry of patient, and family 
history with regard to periodic fever. The effect of colchicine 
therapy, when given, was also evaluated.
Physical signs recorded were: lymphadenopathy, defined as 
the enlargement of lymph nodes at 2 sites; splenomegaly; ser- 
ositis; arthritis; and cutaneous manifestations. The results from 
histopathologic examination of biopsy specimens, when avail­
able, from lymph nodes, rectum, appendix, and skin were col­
lected and reviewed. The corollary from previous abdominal 
surgery was registered with special attention to lymph node 
hyperplasia and the possible occurrence of serositis. Laboratory 
data included complete blood count, erythrocyte sedimentation 
rate, electrolytes, renal function tests, and liver function param­
eters. The level of the immunoglobulins IgA, IgG, IgG l, IgG2, 
IgG3, IgG4 and IgM was documented together with the lowest 
and highest available IgD concentration. Data on the presence 
of circulating immune complexes and concentration of comple­
ment components as well as the presence of auto antibodies were 
recorded as were the results of urinalysis (proteinuria and ery- 
throcyturia). Patients with alternative causes of recurrent fever 
such as tuberculosis, brucellosis, recurrent cytomegalovirus in ­
fections, persisting Epstein-Barr virus infection, and factitious 
and fraudulent fever were omitted from the study.
Results
Demographic features
The literature search identified 35 patients (5,
15, 16, 20, 21, 28, 32, 35, 38, 40, 45, 51, 53, 54). We
were informed about another 6 patients by personal 
correspondence with the following physicians: Dr 
J. Demonty (Liege, Belgium 1990), Prof. Dr. C.M. 
Monciotti (Padua, Italy 1992), Prof. Dr. M. Alcalay 
(Poitiers, France 1992), Dr. D. Jilek (Usti nad La- 
bem, Czech Republic 1992), and Dr. T Espanol 
(Vail d’Hebron, Spain 1993). Another 9 patients 
were referred to members of the International Hy- 
per-IgD Study Group. The total patient population 
comprised 50 patients (28 male and 22 female). 
Most of the patients were of Dutch origin, namely 
28 patients (56%), and 10 patients (20%) from our 
series were born in France (Table 1).
The mean age was 27 years (median, 25.5 yr) 
with a range from 3 to 69 years (Table 1). Twenty 
patients had a positive family history for periodic 
fever. Eighteen patients, all sets of siblings, came 
from 8 families. There were 3 sets of brother-sister 
sibs (patients #2-#3, #13-#14, #21-#22). Two pa­
tients were sisters (patients #33-#34). Ten patients 
were brothers, with 4 brothers in 1 family (patients 
#15-#16, #27-#30, #35-#36-#44-#45, #47-#48). The
mother of patient #6 was diagnosed with familial 
Mediterranean fever and died of amyloidosis. Two 
of the mother’s brothers also had periodic fever, 1 
of them with amyloidosis. The latter had been free
of attacks since renal transplantation in 1979; his 
serum IgD was 4 U/mL. The other brother had a 
serum IgD of 99 U/mL. Patient #6 committed sui­
cide in August 1992. Patient #14 died as a result of 
stroke due to a large frontal calcified meningioma 
in November 1993. The grandmother of patient #24 
had a nephew suffering from recurrent bouts of 
fever and arthritis which could be effectively 
treated with colchicine. His serum IgD was unde­
tectable.
We are not aware of individuals with symptoms 
suggesting the hyperimmunoglobulinemia D and 
periodic fever syndrome in the ancestry of our 
patients. When determined, the serum IgD level in 
the parents and the kin of the patients was without 
exception normal (<100 U/mL). For example, 4 
brothers (patients #35-#36-#44-#45), from a family 
of 6 sons, had elevated serum IgD levels (respec­
tively, 360 U/mL, 398 U/mL, 482 U/mL, 565 U/ 
mL). Two other brothers, the father, and the 
mother did not exhibit periodic fever and had nor­
mal IgD levels (respectively, 38 U/mL, 0.4 U/mL, 
11 U/mL, and 6 U/mL). There is no evidence that 
the disease was transmitted by our patients to their 
children; 9 patients had offspring and none of the 
children showed symptoms of periodic fever. In ­
deed, the serum IgD in the veins of the umbilical 
cord measured just after delivery in 1 patient (#1) 
with an extremely elevated serum IgD (1,607-5,300 
U/mL) was normal (3.3 U/mL), demonstrating that 
IgD does not cross the placenta. Two brothers (#15- 
#16) were mentally retarded and had primary pig­
mentary retinal degeneration and sensory hearing 
loss. They had been previously described in 1968 as 
having etiocholanolone fever (13). At that time, 
during and in between fever attacks, a high level of 
free non-esterified etiocholanolone of the blood had 
been documented. Measurements on subsequent 
occasions in both patients showed normal values of 
this hormone. One further patient (#17) had al- 
antitrypsin deficiency with moderate liver cirrhosis.
Characteristics of the attacks
The median age at onset was 0.5 years with a 
range from the first weeks of life to an extreme of 
53 years (SD 7.8 yr). The age at onset of the disease 
could not be determined for 1 patient (#10), who 
suffered from periodic fever “for years” (54). The 
majority of the patients (34 cases, 68%) developed 
symptoms of periodic fever at a very young age (<1 
year) (Table 1). The average length and frequency 
of the attacks for the individual patients are listed 
in Table 1. The length of the attacks varied both 
from attack to attack and from individual to indi­
vidual, but in general, attacks lasted from 3 to 7 
days. One patient had very short bouts of periodic
TABLE 1. Characteristics of the hyper-IgD syndrome
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Patient Sex Nat
Age at Onset 
(yr)
Current
Age
(yr)
Length of 
Attacks 
(d)
Frequency of 
Attacks
Max Rectal 
Body 
Temperature
(°C)
1 F N 1 32 4-5 1/4 wk 41.3
2 M N 2 30 3-7 1/4-6 wk 41.0
3 F N 0 44 4-5 1/4-6 wk 40.1
4 M N 0 34 3-4 1/4 wk 40.6
5 M N 53 69 13-22 2/yr 40.3
6 M N 8 26 3-7 2/yr >40.0
7 F I 2 27 3-6 1/12-16 wk 39.5
8 M B 3 45 4-5 1/2 wk 39.5
9 M N 12 29 1-2 1/1-4 wk 40.0
10 F N “for years” 42 3-4 1/4 wk 40.1
11 M N 4 49 3-5 1/3-12 wk 40.5
12 M N 3 mo 23 4-5 1/3-4 wk 40.5
13 M UK 3 mo 45 5-6 1/8 wk 40.0
14 F UK 3 mo 61 5-6 1/8 wk 39.6
15 M N 0 35 3-5 1/4 wk 40.1
16 M N 0 36 3-5 1/4 wk 40.5
17 F N 0 24 7 1/2-3 wk 41.0
18 F N 1 43 3-5 1/4 wk >40.0
19 M Fr 6 mo 23 5 1/2-4 wk 40.0
20 F I 2 33 4-7 1/4 wk 40.8
21 M N 3 mo 20 5-6 1/4-6 wk 40.0
22 F N 2 mo 16 5-6 1/4-6 wk 39.0
23 F N 3 mo 19 7 1/4 wk 41.0
24 F N 1 22 6 1/4 wk 41.2
25 F I 1 14 3-4 1/4-8 wk 40.5
26 M N 3 mo 13 2-3 1/3-4 wk 41.0
27 M N 1.5 21 2-3 1/2 wk 40.9
28 F T 5 20 3-4 1/2-4 wk 40.0
29 F T 5 14 7 1/3-8 wk 39.0
30 M N 4 mo 8 2-3 1/4 wk 40.3
31 M N 0 12 7 1/4 wk 39.5
32 M Fr 9 mo 21 3 1/3 wk 40.0
33 F Fr 1 mo 28 3-4 1/8-16 wk 40.0
34 F Fr 5 mo 25 4-6 1/4-8 wk 39.0
35 M N 4-5 31 3-4 1/7-8 wk 40.0
36 M N 10 33 7-10 1/8 wk 41.0
37 F Fr <1  mo 27 7-10 1/4-8 wk 40.1
38 M Fr 1 mo 27 7-14 1/4-6 wk 39.5
39 F Fr 6 mo 24 7-14 3-4/yr 40.0
40 M Fr <1  mo 25 7 1/4-8 wk 40.2
41 F Fr <1  mo 30 7-14 1/4-6 wk 40.0
42 F Fr 3 mo 25 3-5 1/2-3 wk 40.6
43 F C 1 23 2-4 1/2-4 wk 40.0
44 M N 8 27 5-7 1/4-12 wk 40.3
45 M N 4 22 6-7 2-3/yr 39.9
46 F J 4 mo 16 4-5 several times 
a year
39.0
47 M S 8 mo 13 2-3 1/8-12 wk 39.5
48 M S 1 mo 3 2-3 1/4-6 wk 38.5
49 M N 6 mo 7 2-3 1/2 wk 40.0
50 M N 5 wk 3 4-5 1/2-3 wk 41.0
Abbreviations: Nat = Nationality; M = Male; F = Female; N = The Netherlands; I = Italy; B = Belgium; UK = United Kingdom; 
T = Turkey; C = Czech Republic; J  =  Japan; S = Spain; Fr = France; yr = year; mo = month; wk = week.
fever lasting 1 to 2 days. Six patients had attacks 
lasting longer than 7 days, and 1 patient had attacks 
lasting for 6 weeks. The frequency of the attacks 
differed substantially among the individual patients 
(Table 1). While some patients had attacks every 2 
weeks or even weekly, others had attacks only twice 
a year. Most patients had attacks once a month or
bimonthly. Attacks did not appear at fixed inter­
vals, although a hidden periodicity was found in 1 
patient (#1) using sophisticated computer analysis 
(49). The time lapse between episodes, even within 
an individual patient, varied considerably. Symp­
toms did not always resolve completely between 
frequent attacks. There was a tendency among pa­
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tients with the hyper-IgD syndrome toward de­
creased periodicity and severity of attacks with 
increasing age. No definite influence of pregnancy 
on the frequency or severity of the attacks could be 
identified in our cohort.
Fever
A high spiking fever was present in all 50 patients 
(100%). The highest in-hospital recorded rectal val­
ues ranged from 38.5°C to 41.2°C (Table 1). Thirty- 
eight patients (76%) had fevers >40°C. The fever 
was sustained in all. Typically, at onset of an attack, 
the body temperature rapidly rose within a few 
hours to >39°C. During the attack the body tem­
perature remained high and declined only slowly to 
normal values after several days. The pyrexial 
period, on the whole, indicated the boundaries of 
an attack.
Premonitory symptoms
Most patients could predict the advent of attacks 
very shortly before a rise in body temperature. 
Prodromal symptoms include nasal congestion, sore 
throat, backache, severe tiredness, vertigo, head­
ache, and, in some cases, even behavioral changes, 
such as irritability and lassitude. Thirty-eight 
(76%) patients had experienced chills before an 
attack of periodic fever; 12 patients never had a 
chill (Fig. 1).
Precipitating factors
In 27 patients (54%), active immunization with 
either diphtheria toxoid, tetanus toxoid, pertussis, 
influenza, mumps, measles, or rubella vaccine pre­
cipitated a typical attack. Viral infections could 
also trigger febrile attacks. No indications were 
found that certain food ingredients elicited or pre­
vented attacks. Some patients indicated stress as a
number  of pa t i en ts
precipitating factor, and minor surgical interven­
tions triggered febrile episodes in some patients. 
One patient (#1) experienced more attacks shortly 
before the menstrual period (49). Most episodes, 
however, came unexpectedly and were not preceded 
by specific events.
Clinical Features
Abdominal symptoms
Gastrointestinal symptoms were a prominent 
feature of the attacks (Fig. 1). Thirty-six patients 
had abdominal pain, and 14 did not. In some pa­
tients the abdominal symptoms were the main fea­
ture of the attack and defined the severity of the 
attack, resembling an acute abdomen. Appendec­
tomy was performed in 17 cases during an attack; 
on histopathologic examination none of the re­
moved appendices showed signs of inflammation. 
Because of the severity of the symptoms, a laparot­
omy was performed in a few cases, including 2 
brothers (#15-#16) who had severe attacks of ab­
dominal pain suggesting obstruction of the ileum. 
For both patients, extensive adhesions were found 
in the abdominal cavity at first laparotomy; these 
seemed responsible for the mechanical ileus, and 
both patients had swollen intra-abdominal lymph 
nodes. In 3 other patients (#20, #45, #47), laparot­
omy revealed mesenteric adenitis as a cause for the 
abdominal pains. One patient (#47) had a repeat 
laparotomy 1 year later because of severe adhesions. 
Vomiting occurred in 28 patients (56%) during the 
attacks (Fig. 1). Diarrhea was a feature of the febrile 
attacks in 41 patients (82%). Usually the diarrhea 
occurred the first few days after the onset of an 
attack and was watery in nature; a few patients had 
transitory bloody stools. Headache accompanied 
the pyrexial attacks in 26 patients (52%). In 1 
patient (#26), headache was sometimes the domi­
nant feature of an attack.
Articular manifestations
Forty patients (80%) complained of poly-arthral­
gias during pyrexial attacks; 10 patients denied 
articular symptoms (Fig. 1). Arthritis defined as 
swollen and painful joints could be demonstrated 
in 34 of 50 patients (68%) (Fig. 2). The larger joints, 
particularly the knee and ankle, were most com­
monly affected (Table 2), and patients sometimes 
had several joints affected during an individual 
attack. Often, the joint manifestations occurred 
symmetrically. The articular manifestations were 
strongly associated with the febrile attacks, but did 
not necessarily follow a disease flare, and joint 
involvement did occur in the absence of fever. Ar-
o
D ia r rhea  A r th ra lg ia  C h i l l s  Abdom ina l  pain Vom i t ing  Headache
Fig . 1. Symptoms during attacks in 50 patients with the 
hyper-IgD syndrome.
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Fig. 2. Physical signs during attacks in 50 patients with the 
hyper-IgD syndrome.
TABLE 2. Articular manifestations in 34 patients
with the hyper-IgD syndrome
Joint Affected* No. of Patients (%)
Knee 24 (71%)
Ankle 22 (65%)
Wrist 14 (41%)
Elbow 11 (32%)
MCP 8 (24%)
PIP 5 (15%)
MTP 4 (12%)
DIP 3 (9%)
Shoulder 2 (6%)
Hip 2 (6%)
CVC 1 (3%)
Abbreviations: MCP = metacarpophalangeal joints; MTP = 
metatarsophalangeal joints; PIP = proximal interphalangeal 
joints; DIP = distal interphalangeal joints; CVC = cervico ver­
tebral column.
* Arthritis defined as swollen and painful articulations. 
Shoulder, hip or CVC involvement defined as presence of pain 
on passive motion.
thritis was not the first symptom of the hyper-IgD 
syndrome to appear; the interval from onset of the 
disease to the first attack of arthritis ranged from
6 months to 13 years. Febrile attacks with arthritis 
occurred more frequently in the younger age group, 
with a gradual decrease of articular symptoms with 
age. The arthritis in the hyper-IgD syndrome ap­
pears to be benign. From long-term follow-up in 
our patients we have no evidence of joint destruc­
tion, even in patients with severe recurrent arthri­
tis.
Serologic tests for rheumatoid factors were neg­
ative. Synovial fluid was drawn from 3 patients and 
yielded yellow turbid fluid with mucin clots. There 
was a high white blood cell count with more than 
80% polymorphonuclear cells, but cultures from 
synovial fluid proved sterile. Arthroscopy was per­
formed in 1 case (patient #12) and showed a thick­
ened synovium without degenerative changes of the 
articular surface. Biopsy specimens from the syno­
vium of that patient were covered with fibrin de­
number  of pa t i en ts
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posits with macrophages and lymphocytes. Immu­
nofluorescence showed endothelial and intimai de­
posits of C3 together with granular deposits of IgM 
and C3 in the junctional zone between synoviocytes 
and underlying tissue. Immunofluorescence was 
negative for IgD. The picture was compatible with 
active vasoproliferative synovitis. No specific radio- 
graphic changes were noted.
The articular symptoms usually responded to 
nonsteroidal anti-inflammatory drugs or to corti­
costeroids. Prednisone in doses up to 1 mg/kg per 
day for a short period (<2 weeks) was successful in 
most cases.
Manifestations in serous membranes
Involvement of the peritoneum during the at­
tacks was demonstrated in 3 cases (Fig. 2). As 
mentioned, laparotomy in 2 brothers (patients #15- 
#16) revealed severe adhesions, conceivably a con­
sequence of recurrent peritonitis. A repeat laparot­
omy in another case (#47) showed severe abdominal 
adhesions 1 year after surgery because of mesen­
teric lymphadenitis. In all other cases there was no 
evidence of peritoneal, pleural, or pericardial ser­
ositis.
Amyloid
Amyloidosis was not demonstrated in any pa­
tients with the hyper-IgD and periodic fever syn­
drome despite long durations of symptoms. Rectal 
biopsy was performed in 16 patients and showed no 
amyloid. Except for the family of patient #6, there 
was no evidence of clinical manifestations of amy­
loid in any family members of the patients with the 
hyper-IgD syndrome.
Lymphadenopathy and splenomegaly
Lymphadenopathy during the attacks was an al­
most pathognomonic finding in our series and was 
present in 47 patients (94%). Only 3 patients did 
not show palpable lymph nodes (Fig. 2). Character­
istically, the lymph nodes increased in size during 
the attacks, with the cervical region most com­
monly involved. Inguinal and axillary lymph nodes 
were also affected. The lymph nodes were rubbery 
and/or tender on palpation. In cases where laparot­
omy or lymphangiography had been performed, in­
volvement of mesenteric, iliac, and paralumbar 
lymph nodes was noted. In 19 cases, lymph nodes 
were biopsied, and, in general, specimens showed 
hyperplasia, presence of plasma cells, and signs of 
aspecific reactive lymphadenitis, that is, nonspe­
cific changes. A palpable spleen during febrile epi­
sode was found mainly in children. This feature 
was demonstrated in 24 patients (48%) during the
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attacks (Fig. 2). In contrast to lymphadenopathy, 
splenomegaly became a rare symptom of the febrile 
attacks with increasing age.
Cutaneous manifestations
An extensive review of skin lesions in the hyper- 
IgD syndrome has been published elsewhere (11). 
In brief, 41 patients (82%) demonstrated skin le­
sions with pyrexial attacks, and 9 never had cuta­
neous manifestations (Fig. 2). Erythematous mac­
ules were the most common skin lesions (26 pa­
tients), followed by papules (17 patients) (Table 3). 
A representative eruption usually consisted of mul­
tiple erythematous macules which could be solitary 
or confluent. The larger macules sometimes showed 
annular formation with normal skin centrally and 
slightly irregular margins. The lesions were wide­
spread but predominated on the limbs. Biopsies 
from affected skin mostly showed endothelial swell­
ing and perivascular inflammatory infiltrates.
Laboratory Tests
General
In all patients, attacks were accompanied by a 
sharp rise in the erythrocyte sedimentation rate 
(ESR), with a mean ESR of 90 mm/h (range, 20- 
150). During the episodes, leukocytosis was noted 
in all patients with a mean leukocyte count of 
18.7xl09/L (range, 4.6-42xl09/L). Twenty-one pa­
tients (42%) were observed with counts in excess 
of 20x109/L- The leukocytosis was related to neu­
trophilia often with immature neutrophils and toxic 
granulation. Following an attack, the leukocytosis 
and ESR consistently resolved to normal values. In 
all 50 patients, the infection surveys were nondi­
agnostic; these included cultures of blood, urine, 
and other sites as well as serologic tests for viruses. 
Mild transient erythrocyturia, as defined 1+ by 
dipstick, was observed in 8 patients during episodes 
with high spiking fever. In between attacks the 
results of the urinalysis were normal in all patients.
TABLE 3. Cutaneous manifestations in 41 patients
with the hyper-IgD syndrome
Cutaneous Manifestation* No. of Patients (%)
Erythematous macules 26 (63%)
Erythematous papules 17 (41%)
Urticaria 10 (24%)
Erythematous nodules 9 (22%)
Morbilliformic rash 8 (19%)
Non-defined exanthema 8 (19%)
Annular erythema 6 (15%)
Purpura 5 (12%)
Petechia 4 (10%)
* Some patients had more than 1 skin lesion.
The renal function remained normal in all patients. 
In 1 patient (#17) with concomitant a l-antitrypsin 
deficiency, the hepatic function was moderately 
impaired. Circulating immune complexes, usually 
measured by the C lq binding assays, were present 
during and in-between attacks in low titers in 10 
patients (20%). There were no auto-antibodies. 
Serum complement was determined in 46 patients; 
it was normal in the majority and slightly reduced 
in 3 patients. C3 levels were mildly elevated in 8, 
and C4 levels were mildly increased in 7 patients. 
No complement deficiencies were found. When 
tested, the cellular and humoral immunity did not 
differ from normal controls. Thus, the hyper-IgD 
syndrome does not seem to represent an immuno­
deficiency state.
Immunoglobulins
An elevated serum IgD is essential for the diag­
nosis of the hyper-IgD syndrome. Table 4 lists the 
highest and the lowest serum IgD level for a given 
patient. The concentrations vary from 0 U/mL to 
5,300 U/mL. We could not detect a relationship 
between the level of the serum IgD and either the 
frequency or severity of attacks. In 3 patients (#27, 
#31, and #48) the onset of periodic fever preceded 
the rise of serum IgD. Symptoms in these patients 
started early in life, and the first analyses revealed 
normal serum IgD in all 3 (respectively, 11, 0, and 
39 U/L). After 41 months, 26.5, and 37 months, 
respectively, the serum IgD level increased to more 
than 100 U/mL (218, 158, and 600 U/mL, respec­
tively). Neither frequency nor intensity of the at­
tacks changed in this period of rising IgD. The 
serum immunoglobulin concentrations are given in 
Table 4. The serum IgG was normal in 31 patients 
and elevated in 19 patients (>14.6 g/L). On average 
the serum IgG was 13.5 g/L (range, 6.03-27.2 g/L). 
The IgM was within normal range in 21 patients, 
increased in 17 (>1.5 g/L), and decreased in 12 
patients (<0.7 g/L). The mean value was 1.42 g/L 
(range, 0.13-4.93 g/L). A striking elevation of 
serum IgA levels was noted in our series. As many 
as 42 patients (82%) had concomitant elevated 
serum IgA levels (>2.6 g/L). Only 8 patients had 
normal serum levels of IgA. The mean serum IgA 
in our series was 5.54 g/L with a range from 1.4 to 
19.0 g/L. While the IgGl, IgG2, and IgG4 were 
virtually within normal limits in our patients, IgG3 
was elevated in 13 (31%) of the 42 patients tested. 
In 1 patient the value was below the lower limit.
Management
The attacks of the fever with the associated 
symptomatology were self-limiting, and, in general,
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TABLE 4. Levels of immunoglobulins A, G l, G2, G3, G4, G, M, and D in patients with the hyper-IgD syndrome
Patient
IgA
(g/L)
IgG l
(g/L)
IgG2
(g/L)
IgG3
(g/L)
IgG4
(g/L)
IgG
(g/L)
IgM
(g/L)
IgD min 
(U/mL)
IgD max 
(U/mL)
1 2.74 4.17 0.51 0.28 0.08 6.03 0.53 1607.0 5300
2 6.83 7.55 2.58 1.50 0.20 8.72 0.58 199.0 674
3 3.65 13.00 2.38 1.22 0.27 10.80 1.75 450.0 1383
4 5.70 8.70 4.05 0.85 0.20 12.50 1.50 778.0 991
5 2.90 5.55 4.49 0.39 0.39 10.60 3.30 238.0 280
6 3.30 2.86 3.26 0.56 0.83 11.30 0.99 34.0 196
7 5.36 7.69 2.04 0.86 0.97 15.80 1.78 186.0 1390
8 3.17 4.28 0.85 0.47 0.18 8.28 0.13 645.0 1050
9 1.85 4.75 2.18 0.34 0.29 8.80 1.85 64.0 193
10 3.70 5.47 3.19 0.59 0.04 10.80 1.80 106.0 434
11 1.90 8.20 2.55 0.71 0.10 11.40 1.10 205.0 450
12 3.30 7.22 2.02 0.92 0.24 14.30 1.80 1450.0 2000
13 5.20 8.33 4.70 1.22 0.38 13.30 0.56 318.0 900
14 7.20 11.50 0.89 0.54 0.09 14.70 0.17 1012.0 3187
15 7.90 15.00 1.90 1.17 0.24 16.20 0.60 492.0 1170
16 8.80 8.00 1.30 0.76 0.15 9.70 0.50 472.0 680
17 6.30 5.73 2.68 0.66 0.41 10.80 1.40 182.0 491
18 2.60 4.82 1.97 0.97 0.04 9.60 1.20 520.0 1470
19 5.07 9• 9• 9• 9• 11.50 0.79 800.0 950
20 4.00 9• 9• 9• 9• 11.50 0.96 637.0 680
21 4.97 9.18 2.76 1.33 0.48 14.60 0.62 780.0 2340
22 2.22 8.66 0.78 0.95 0.04 9.82 0.78 750.0 3250
23 2.94 13.70 2.53 1.74 0.28 10.90 0.97 340.0 476
24 1.50 1.64 2.02 0.58 0.94 16.60 1.70 154.0 231
25 7.25 18.80 1.84 1.82 0.25 19.00 0.27 1837.0 2805
26 4.40 11.30 1.75 1.30 0.10 12.10 0.90 1445.0 4224
27 10.50 5.47 1.06 1.33 0.04 6.96 0.83 230.0 1731
28 1.53 9• 9• 9• 9• 13.10 1.92 9• 220
29 2.74 9• 9• 9• 9• 21.90 3.39 9• 156
30 10.50 10.50 1.82 2.90 0.18 16.60 4.93 0 1898
31 7.67 9.05 2.35 1.02 0.91 10.30 1.27 11.0 656
32 4.38 9.30 1.30 0.38 0.85 17.70 1.90 100.0 145
33 5.08 8.90 1.50 0.72 0.13 17.40 2 .22 231.0 936
34 5.97 7.25 1.90 0.85 0.13 14.60 1.35 432.0 636
35 4.40 9.24 1.57 0.89 0.21 14.40 0.70 302.0 398
36 7.74 8.39 1.67 1.32 0.13 13.30 0.66 266.0 360
37 19.00 15.80 3.15 1.45 0.08 16.50 1.50 283.0 1841
38 8.40 9• 9• 9• 9• 12.30 0.94 637.0 1416
39 10.90 9• 9• 9• 9• 21.50 1.36 849.0 1203
40 6.60 6.40 1.25 0.11 0.09 7.90 1.71 134.0 414
41 4.70 9• 9• 9• 9• 13.00 1.75 141.0 793
42 5.82 7.20 1.15 0.85 0.02 19.10 0.49 632.0 1026
43 13.10 10.00 2.54 1.02 0.41 16.70 0.56 15.1 1743
44 7.38 8.59 2.02 1.46 0.14 25.50 2.60 482.0 960
45 2.16 7.68 1.69 1.15 0.39 14.80 2.80 286.0 565
46 2.80 9• 9• 9• 9• 27.20 1.36 329.0 1310
47 12.50 13.40 1.38 4.56 0.46 16.50 2.28 950.0 1100
48 4.41 5.60 3.00 0.88 0.76 10.30 3.49 39.0 600
49 2.30 7.70 1.20 0.40 0.25 10.20 1.20 345.0 400
50 1.40 6.40 0.40 0.30 0.10 9.30 1.30 102.0 209
Abbreviations: ? = not measured.
patients were symptom free between attacks. Med­
ical therapy was not convincingly successful, since 
attack-free periods occurred without medication, 
making the results of treatment difficult to assess. 
Colchicine, which was prescribed for 33 patients, 
modified the frequency pattern of the pyrexial at­
tacks to some extent; in 5 patients it seemed to 
diminish the intensity, frequency, and duration of 
the attacks. In 28 patients, the drug was of no 
benefit and was therefore discontinued. In 1 patient
(#8), methylprednisolone at a dose of 8 mg/d was 
reported to abrogate the attacks completely. A few 
other patients had some benefit from corticoster­
oids, which ameliorated the severity of the attacks.
One patient (#3) had been disease free for 6 years 
with cyclosporin (200-300 mg/d), but her brother 
(#2) did not benefit from this therapy. One patient 
(#20) was treated with intravenous immunoglobu­
lins administration (0.15 g/kg at 2 week intervals); 
during the treatment, the number and severity of
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the attacks diminished. This therapy did not influ­
ence the attack rate in 4 other patients (#33-#34, 
#47-#48).
Prognosis
The hyper-IgD syndrome does not seem to have 
an appreciable effect on mortality. All patients lived 
except 2 (patients #6 and #14). The first patient 
died of suicide, the other died as a result of stroke. 
As mentioned, the febrile attacks tended to be less 
frequent and less severe with increasing age. Apart 
from age, we could not detect any other factor 
influencing the attacks of periodic fever. Patients 
with this syndrome do not appear to be at great 
risk for development of amyloidosis. In our series, 
patients with hyper-IgD syndrome did not have an 
increased risk of infections. One patient (#1) devel­
oped a toxic streptococcal syndrome post partum. 
Malignancy was detected in only 1 case (#3) (lim­
ited breast carcinoma; T1N0M0).
Discussion
We have performed a clinical and laboratory 
survey in 50 patients with the hyper-IgD syndrome. 
As with other entities characterized by periodic 
fever the diagnosis of hyper-IgD is syndromal. 
Table 5 lists the features typical for the diagnosis. 
This discussion will focus on the clinical and labo­
ratory features at presentation and on the thera­
peutic possibilities. Furthermore, we will demarcate 
the hyper-IgD syndrome from other periodic fever 
syndromes like familial Mediterranean fever, fa­
milial Hibernian fever, systemic-onset juvenile 
chronic arthritis, and adult-onset Still disease.
So far, the hyper-IgD syndrome has been ob­
served predominantly in patients from Europe, with 
the majority of patients originating from the Neth­
erlands (26 patients). A considerable number were
TABLE 5. Features of the hyper-IgD syndrome
General
High IgD (>100 U/mL), measured on 2 occasions at least 1 
month apart 
Elevated IgA (>2.6 g/L)
Recurrent attacks 
During Attacks 
Elevated ESR and leukocytosis 
Abrupt onset of fever (>38.5°C)
Lymphadenopathy (cervical)
Abdominal distress 
Vomiting 
Diarrhea 
Pain
Skin manifestations (erythematous macules and papules)
Arthralgias/Arthritis
Splenomegaly
from France (10 patients) but also from other 
southern countries like Italy (3 patients), Turkey 
(2 patients), and Spain (2 patients). This distribu­
tion probably reflects underreporting from other 
parts of the world. The syndrome seems to be evenly 
distributed in males and females (1:0.78), and it 
clusters in families. We found sibs, male as well as 
female, with the disease from 8 different families, 
suggesting an as yet unknown hereditary pattern. 
There are no indications for the hyper-IgD syn­
drome in the ancestry of our patients. Our material 
does not show that either male or female patients 
will pass the disease to the next generation. Typi­
cally, the hyper-IgD syndrome has a juvenile onset 
and in our series the median age at onset of symp­
toms was 0.5 years. Most patients (68%) had their 
first episode before the age of 1 year. One patient 
had a very late onset of complaints and had his 
first attack at the age of 53. The frequency of the 
attacks varied widely among patients. Most pa­
tients had attacks every 4-8 weeks lasting 3-7 days 
on average.
The prodromes were rather nonspecific but in­
cluded nasal congestion, dry throat, severe fatigue, 
vertigo, and headache. At the onset of an attack the 
body temperature rose within hours to values above 
39°C, frequently preceded by rigors. Other clinical 
symptoms may accompany the attacks. The major­
ity of patients showed enlarged lymph nodes with 
crises, and splenomegaly was detected in approxi­
mately 48% of patients. The lymphadenopathy 
could be extensive with involvement of not only 
cervical lymph nodes but also axillary, inguinal, 
and mesenteric regions. On palpation the lymph 
nodes were rubbery and tender. The lymphadenop­
athy was consistently present with subsequent 
crises in most patients. Splenic and hepatic enlarge­
ment was more often seen in the younger age group. 
Abdominal pain was common with attacks; diar­
rhea occurred in a majority of patients (82%), and 
56% of patients in our series had vomiting. The 
question remains to what extent the abdominal 
complaints were due to inflammation of the serosal 
membranes. In 3 cases (#15-#16, #47) there was 
evidence for peritonitis with a mechanical ileus 
caused by the formation of adhesions. Laparotomy 
performed in the acute stage showed gross enlarge­
ment of the abdominal lymph nodes. It is likely 
that the abdominal symptoms in the hyper-IgD 
syndrome arise from inflammation of gut-associ­
ated lymphoid tissue. Polyarthralgias during at­
tacks were noted in 80% of the cases. Arthritis was 
reported in 68% of patients in our series. In most 
instances it occurred a few years after the initial 
attacks. Usually the larger joints were affected, and 
no evidence of destructive arthritis was found (12). 
Skin manifestations were a part of the clinical
1
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spectrum. In our series, 82% had skin lesions during 
attacks, most commonly macular or papular ery­
thematous lesions and histologic evidence of vas­
culitis.
A characteristic phenomenon of the syndrome is 
the ability of secondary immunizations to elicit an 
attack (21, 38). This was documented in 54% of 
patients in this series and could be a clue to early 
diagnosis. The acute-phase response, reflected by 
the leukocytosis, neutrophilia, and raised ESR, was 
a consistent finding. The persistently elevated pol­
yclonal serum IgD (>100 U/mL) was a feature 
shared by all patients. In the bone marrow, the 
number of IgD-producing plasma cells was in­
creased (55). As far as studied, the serum IgD k/\ 
ratio was raised (20). Serum IgA was elevated in 
82% of patients. In 19 patients (38%), serum IgG 
was elevated. Determination of IgG subclasses re­
vealed an elevated IgG3 in only 31% of the 42 
patients tested, in contrast to the study by Harald- 
son et al (20) who studied 5 children (#21-#22, #27- 
#30, #31) and found IgG3 elevated in all.
Serum IgD in normal individuals shows a trimo- 
dal frequency distribution dispersion pattern (14), 
decreasing slightly with increasing age (50). In nor­
mal subjects cigarette smoking is associated with 
elevated serum IgD level, and stopping results in a 
decline of IgD levels (1); also, maternal IgD levels 
increase with the duration of the pregnancy (24, 
25).
An elevated serum IgD may be found in various 
diseases, including Hodgkin disease (10), sarcoido­
sis and tuberculosis (8), aspergillosis (29), ataxia- 
telangiectasia (30, 41) and AIDS (9, 33). The role 
of the elevated serum IgD in the pathogenesis of 
the hyper-IgD attacks remains uncertain. First, 
there appears to be no relation between the serum 
concentration of IgD and the frequency and/or 
severity of the attacks; second, the level of the IgD 
does not fluctuate with attacks (35). Third, Harald- 
son et al (20) observed the onset of the hyper-IgD 
syndrome before the rise of the serum IgD, but that 
does not necessarily indicate that the elevated IgD 
is an epiphenomenon. It was previously hypothe­
sized that IgD-containing complexes played a 
pathophysiologic role (53). This theory was sup­
ported by the finding of erythrocyturia and the 
detection of perivascular deposits of IgD in lesional 
skin from a patient (#1) with the hyper-IgD syn­
drome (5). Few patients (11%) in our series showed 
transitory erythrocyturia with attacks. Thus, the 
issue of the role of immune complexes is still con­
fusing. In a study of a variety of patients with 
elevated serum IgD levels, polyethyleneglycol 6000 
complexes containing IgD were noted in patients 
with and without periodic fever (21); such com­
plexes were present both during and between at­
tacks. Further research is needed to establish 
whether the elevated IgD should be regarded as a 
secondary or independent phenomenon. Despite 
the unknown function and role of IgD in the path­
ogenesis, patients with the hyper-IgD syndrome 
share a remarkably similar clinical picture, and the 
elevated serum IgD serves well as a marker of the 
syndrome. The role of circulating IgD in health and 
disease remains equivocal. Studies in normal pop­
ulations showed that IgD is very low in cord blood 
and that serum levels rise in early childhood and 
tend to decline with progressing age (23, 27, 50, 59).
Antibody activity in the IgD class has been found 
against insulin (26), against Escherichia coli in sub­
jects infected with that organism (46), against 
wheat in patients with celiac disease (2), and 
against tartrazine in certain patients with chemical 
hypersensitivity (56). We were unable to detect IgD 
antibodies against milk in 2 of our patients (Van 
der Meer and Van Nieuwkoop, unpublished obser­
vations). Interestingly, apart from the elevated IgD, 
a consistently elevated serum IgA level was seen in 
41 of our patients (82%). Furthermore, in our pa­
tients both humoral and cellular immunity ap­
peared normal and there is no increased suscepti­
bility to infections (21).
Drug therapy with colchicine, the first-line drug 
in familial Mediterranean fever (42), has been dis­
appointing in the hyper-IgD syndrome notwith­
standing the early impression of benefit (53). 
Nevertheless, the prognosis of patients with the 
hyper-IgD syndrome is good. Apart from the recur­
rent febrile attacks there are, as yet, no indications 
of an excess morbidity, for example, the develop­
ment of amyloidosis.
Differentiation from other periodic fever syn­
dromes such as familial Mediterranean fever, sys­
temic type of juvenile chronic arthritis, adult-onset 
Still disease, and familial Hibernian fever remains 
difficult since all diagnoses are made syndromally. 
Most classifications use several clinical parameters, 
and considerable overlap may result. There are 
nevertheless some clear differences between the 
mentioned periodic fever syndromes and the hyper- 
IgD syndrome (Table 6). First, the serum IgD is 
normal in the other syndromes.
Familial Mediterranean fever (FMF) is charac­
terized by idiopathic, recurring, self-limited febrile 
attacks with serositis (31). There is a preference for 
people from Mediterranean ancestry, particularly 
Sephardic Jews (48) and Armenians (44), but the 
disease may also occur in Turks, (36) French peo­
ple, (47) Germans, (6) Swedes, (4) Italians (7) and 
Dutch people (17, 19, 43). In contrast to FMF, the 
diagnosis of the hyper-IgD syndrome, so far, has 
been made mainly in Europeans. The question is, 
of course, whether some of the non-Mediterranean
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TABLE 6. Clinical differences between periodic fever
syndromes
Clinical
Symptom
Systemic- 
Familial Onset Adult-Onset 
Mediterranean Juvenile Still Hyper-IgD 
Fever Rheumatoid Disease
Arthritis
Age at on­ <20 <15 >15 <10
set (yr)
Swollen — ± + ++
lymph
nodes
Carditis + + + —
Arthritis deforming deforming deforming benign
Pleuritis + + + —
Peritonitis + — 4- —
Amyloidosis + ± --- —
Familial + — — +
IgD Normal Normal Normal Elevated
Country of 
origin
Sephardic 
Jews, Arabs
Various Various
countries
world­
wide
Europe ?
Treatment Colchicine NSAIDs
Cortico­
steroids
NSAIDs
Cortico­
steroids
9
•
Abbreviations: — = absent; + = often present; ++ = promi­
nent; ± = occasionally present; ? = uncertain; NSAIDs = 
nonsteroidal anti-inflammatory drugs.
patients with periodic fever reported as FMF are 
actually suffering from the hyper-IgD syndrome. 
We have traced the Dutch patient described by 
Haex et al (19) in 1963 as FMF and could exclude 
the hyper-IgD syndrome (IgD <  100 U/mL).
The hyper-IgD syndrome has an earlier onset 
than FMF. About 50% of the FMF patients had 
their first attack before the age of 10 years (31). In 
our series, 96% of patients had attacks before the 
age of 10.
Serositis is a hallmark of FMF. In contrast to 
FMF, pleuritis has not been encountered as a fea­
ture of hyper-IgD syndrome. Peritonitis, which oc­
curs in over 90% of the cases of FMF, is uncommon 
in the hyper-IgD syndrome (31).
Joint involvement with a preference for the large 
joints is a feature of both syndromes. The arthritis 
in FMF may present in a short acute or a protracted 
form (18). The first type resembles the arthritis in 
the hyper-IgD syndrome, whereas the longstand­
ing type does not seem to occur in the hyper-IgD 
syndrome (3, 18).
Enlargement of lymph nodes, a key finding in the 
hyper-IgD syndrome is exceptional in FMF (3, 47). 
Splenomegaly, which was present in 48% of pa­
tients in our series, was found in less than 3% in 1 
series of 175 patients with FMF (3). Diarrhea is 
equally rare in FMF but it occurs in 82% of patients 
with hyper-IgD during attacks.
Another difference between FMF and the hyper- 
IgD syndrome is the incidence of amyloidosis. In
FMF this ranges from 0 to 60%, whereas it is, as 
yet, rarely if ever encountered in the hyper-IgD 
syndrome.
In children, it may be difficult to differentiate 
the hvper-IgD syndrome from the systemic-onset 
juvenile rheumatoid arthritis (38, 39). The latter 
syndrome presents with high spiking, intermittent 
fever, an evanescent maculopapular rash, often 
with lymphadenopathy and splenomegaly. The ar­
ticular findings range from arthralgia to florid 
polyarthritis and may only occur weeks after the 
onset of the first symptoms (39). Pericarditis and 
pleuritis are common in systemic-onset juvenile 
rheumatoid arthritis; these complications have not 
been seen in the hyper-IgD syndrome.
In the hyper-IgD syndrome, the fever is more of 
a remittent type, and the skin lesions are not eva­
nescent and persist during the whole febrile episode 
(11). Adult-onset Still disease has a clinical picture 
similar to the juvenile type (34, 52). The average 
age at onset of adult-onset Still disease is 30 years, 
which is appreciably higher than in the hyper-IgD 
syndrome. Familial clustering is not a feature of 
adult-onset Still disease. A sore throat, which can 
be found in up to 92% of the patients with adult- 
onset Still disease (34, 37), is not prominent in the 
hyper-IgD syndrome. Pleuritis and pericarditis oc­
cur in 25%-30% of patients with adult-onset Still 
disease and not in the hyper-IgD syndrome (34, 58). 
In adult-onset Still disease, swelling of lymph nodes 
(60%-71% of patients) and abdominal pains (20%- 
23%) are less frequent than in the hyper-IgD syn­
drome (34, 58). In contrast with the hyper-IgD 
syndrome, the arthritis in adult-onset Still disease 
is deforming in approximately 30% of cases (34).
Both syndromes show an accelerated erythrocyte 
sedimentation rate, a leukocytosis and a neutro­
philia. An interesting laboratory finding in the 
adult-onset Still disease is an increased serum IgA, 
which was found in 34% of patients of Ohta et al 
(34); in the hyper-IgD syndrome this occurs in 82% 
of patients. Disturbed hepatic enzyme levels, com­
mon in adult-onset Still disease (up to 71% of 
patients) has not been observed in the hyper-IgD 
syndrome (34).
Familial Hibernian fever occurs in Irish stock 
with attacks of fever and localized myalgia and 
painful erythema. Normal serum IgD levels are 
found in these patients (57).
Conclusion
The hyper-IgD syndrome is a condition charac­
terized by recurrent febrile attacks usually of very 
early onset (<1 year). The diagnosis has been made 
in 50 patients mainly from Europe. There is an
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even male-female distribution. Typical attacks oc­
cur every 4-8 weeks and last about 3-7 days with a 
large individual variation. The attacks feature the 
acute onset of high spiking fever, sometimes pre­
ceded by chills. Abdominal pains, vomiting, and 
diarrhea are associated with the episodes. Headache 
and arthralgias occur frequently with attacks. On 
physical examination during the attacks, swollen, 
tender lymph nodes, most often in the cervical 
region, can be palpated. Especially in the young 
age-group, splenomegaly may be found. Non-de­
structive recurrent arthritis, mainly in the larger 
joints, can be demonstrated in many patients. Dur­
ing the attacks, most patients have erythematous 
macules and papules, with histologic signs of cuta­
neous vasculitis.
Laboratory testing during attacks reveals an 
acute-phase response (leukocytosis, neutrophilia, 
and a steeply elevated ESR). The diagnosis is based 
on the clinical picture and a persistently elevated 
serum IgD level (>100 U/mL) (Table 5). Most 
patients also have a elevated serum IgA. The oc­
currence of febrile attacks elicited by various im­
munizations is a clue to early diagnosis. The path­
ogenesis of the syndrome is unknown. The attacks 
tend to diminish with age but patients seem to have 
symptoms from the hyper-IgD syndrome through­
out life. Management of the syndrome remains 
unsatisfactory. Colchicine is of value in only a 
minority of patients. The hyper-IgD syndrome 
clearly differs from other periodic fever syndromes 
like the adult-onset Still disease and familial Med­
iterranean fever.
Summary
We studied 50 patients (28 male and 22 female) 
with the hyper-IgD and periodic fever syndrome. 
Most patients originated from Europe, namely The 
Netherlands (28 cases; 56%), France (10 cases, 
20%), and Italy (3 cases, 6%), but 1 patient was 
from Japan. A hereditary component is suggested 
by 18 patients coming from 8 families. The syn­
drome is typified by a very early age at onset 
(median, 0.5 years) and life-long persistence of 
periodic fever. Characteristically, attacks occur 
every 4-8 weeks and continue for 3-7 days, but the 
individual variation is large. Attacks feature high 
spiking fever, preceded by chills in 76% of patients. 
Lymphadenopathy is commonly present (94% of 
patients). During attacks, 72% of patients com­
plained of abdominal pains, 56% of vomiting, 82% 
of diarrhea, and 52% of headache. Joint involve­
ment is common in the hyper-IgD syndrome with 
poly-arthralgia in 80% and a non-destructive ar­
thritis, mainly of the large joints (knee and ankle),
in 68% of patients. Eighty-two percent of patients 
reported skin lesions with some attacks; these dem­
onstrated vasculitis histologically. Serositis has 
been seen in only 3 patients (6%), while amyloidosis 
has not been recorded in any of the patients with 
this syndrome. Immunizations precipitated attacks 
in 54% of patients. All patients had a persistently 
elevated serum IgD level (>100 U/mL), and in 82% 
of cases the serum IgA was likewise elevated. Dur­
ing attacks there is an acute-phase response ad­
judged by leukocytosis, neutrophilia, and increased 
ESR. The etiology remains to be elucidated, and 
treatment is supportive. The hyper-IgD syndrome 
is distinct from other periodic fever syndromes like 
systemic-onset juvenile rheumatoid arthritis, adult- 
onset Still disease, and familial Mediterranean fe­
ver.
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